GlassScriptPhysician profile
James F Freeman
NPI 1902805823
$140,887.08
in general payments reported to CMS, 2019-2025
39 companies · $1,178 in 2025
The $1,178 reported for 2025 was more than what 81% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,099 · 2020: $735 · 2021: $981 · 2022: $129K · 2023: $5,991 · 2024: $2,349 · 2025: $1,178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $5,344 · Food and Beverage: $2,648 · Consulting Fee: $1,500 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $5,343.75 |
| Food and Beverage | $2,648.34 |
| Consulting Fee | $1,500.00 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grace Medical, INC. | $127,500.00 | 2022 | |
| Rxsight INC | $7,220.47 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Johnson & Johnson Surgical Vision, INC. | $584.77 | 2019-2024 | Amo Phaco Needle, Tecnis Iol |
| Allergan, INC. | $524.34 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $499.38 | 2022-2025 | Envista Envy Iol, Vyzulta, Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $442.97 | 2019-2021 | |
| Abbvie INC. | $436.17 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $336.64 | 2020-2022 | |
| Alcon Vision LLC | $329.81 | 2019-2025 | Lensx, Clareon, Clareon Panoptix Pro |
| Carl Zeiss Meditec USA, INC. | $293.09 | 2022-2023 | Visumax, Quatera 700 |
| Harrow Eye, LLC | $250.11 | 2024-2025 | Vevye |
| Rayner Intraocular Lenses Limited | $215.02 | 2022-2025 | Rayone Aspheric, Rayone Spheric, Rayone Emv |
| Glaukos Corporation | $207.99 | 2021-2025 | Idosetr, Istent Infinite |
| Kala Pharmaceuticals, INC. | $189.30 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $167.30 | 2019-2023 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$30,075,970.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.